Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations
Nature Biotechnology · 2025-11 · 43 (11) · 1778-1782
DOI: 10.1038/s41587-024-02488-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Biotechnology, online erschienen am 27.11.2024. Verfasst von Grégoire Cullot und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland. gregoire.cullot@biol.ethz.ch. Hauptthemen laut MEDLINE: Gene Editing, DNA-Activated Protein Kinase, Pyrazoles, Recombinational DNA Repair. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020), Deutsche Forschungsgemeinschaft (German Research Foundation).
Abstract (Originalsprache)
The DNA-PKcs inhibitor AZD7648 enhances CRISPR–Cas9-directed homology-directed repair efficiencies, with potential for clinical utility, but its possible on-target consequences are unknown. We found that genome editing with AZD7648 causes frequent kilobase-scale and megabase-scale deletions, chromosome arm loss and translocations. These large-scale chromosomal alterations evade detection through typical genome editing assays, prompting caution in deploying AZD7648 and reinforcing the need to investigate multiple types of potential editing outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland. gregoire.cullot@biol.ethz.ch.
- Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
- Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.
- Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- CSL Behring Research, Bern, Switzerland.
- Swiss Institute for Translational Medicine sitem-insel, Bern, Switzerland.
Förderung
- EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
- Deutsche Forschungsgemeinschaft (German Research Foundation)
Zitieren
APA
Cullot, G., Aird, E. J., Schlapansky, M. F., Yeh, C. D., van de Venn, L., Vykhlyantseva, I., Kreutzer, S., Mailänder, D., Lewków, B., Klermund, J., Montellese, C., Biserni, M., Aeschimann, F., Vonarburg, C., Gehart, H., Cathomen, T., & Corn, J. E. (2025). Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. Nature Biotechnology, 43(11), 1778-1782. https://doi.org/10.1038/s41587-024-02488-6
Vancouver
Cullot G, Aird EJ, Schlapansky MF, Yeh CD, van de Venn L, Vykhlyantseva I, et al. Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. Nature Biotechnology. 2025;43(11):1778-1782. doi:10.1038/s41587-024-02488-6
BibTeX
@article{Cullot2025,
author = {Cullot, Grégoire and Aird, Eric J and Schlapansky, Moritz F and Yeh, Charles D and van de Venn, Lilly and Vykhlyantseva, Iryna and Kreutzer, Susanne and Mailänder, Dominic and Lewków, Bohdan and Klermund, Julia and Montellese, Christian and Biserni, Martina and Aeschimann, Florian and Vonarburg, Cédric and Gehart, Helmuth and Cathomen, Toni and Corn, Jacob E},
title = {Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations},
journal = {Nature Biotechnology},
year = {2025},
volume = {43},
number = {11},
pages = {1778--1782},
doi = {10.1038/s41587-024-02488-6}
}
EUVIMED